In this research, hydrophobic DESs were successfully prepared using components with hydrophobic and sulfydryl group, which were applied to develop a green and eco-friendly method to extract and detect the cadmium (Cd) in herbal medicine (HM).The basic properties of the DESs were studied, which showed good hydrophobicity, low d. and sufficient absorption capacity.In extraction process, the extraction efficiency (EE) of Cd employing proposed process ranged from 89.12 %∼94.59 % and the maximal enrichment factor (EF) was 46.85.The DES based method demonstrated a good linear response in the range of 1 ∼ 50 μg·L^-1 with a detection limit (LOD) of 0.29 μg L^-1, which was detected by Inductively coupled plasma mass spectrometry (ICP-MS).Addnl., the accuracy of method (as recoveries %) was obtained with the recoveries ranging from 98.38 %∼105.48 %.The extraction process was also compared with microwave digestion (MD) method and showed basically equivalent effect with good propensity to enrichment.The mechanism was explored by DFT calculation to reveal the interaction of extraction process.The greenness of the proposed method was also evaluated using the Green Anal. Procedure Index (GAPI) and Anal. Eco-Scale (AES), which indicated excellent environmental protection.This study successfully prepared novel DESs and established an eco-friendly and effective anal. process integrating adsorption, collection, separation and detection for the detection of heavy metals in HM, and the DESs were contributed to the first three parts as a multifunctional role.The absorption mechanism related to the formation of mol. complexes in quantum chem. perspective, which were attribute to the electrostatic attraction and H⁺ exchange between Cd and adsorbent.This method showed vast potential in heavy metal research involving complex matrixes such as HM and its processed products, and the proposed process provides the way for a greener alternative for Cd extraction rather than conventional polluting processes.

01 Jan 2025·Journal of Ethnopharmacology

Mechanism of Biqi capsules in the treatment of gout based on network pharmacology and experimental verification

Article

Author: Wu, Yuzheng ; Wang, Yang ; Du, Simiao ; Zhang, Yi ; Wang, Tao ; Cheng, Meifang ; Chen, Qian ; Zhang, Xiangqi ; Wang, Dan ; Li, Ge ; Yan, Siya ; Bu, Ruizhen

ETHNOPHARMACOLOGICAL RELEVANCEGout is a crystal-related arthropathy caused by monosodium urate (MSU) deposition, resulting from purine metabolism disorders and hyperuricemia (HUA). Gout belongs to the traditional medicine category of Bi syndrome. Biqi capsules (BQ) is a traditional Chinese medicine formula used to treat Bi syndrome. The BQ prescription is derived from the ancient prescription of Hua Tuo, a famous physician in the Han Dynasty.AIM OF THE STUDYTo study the effect and mechanism of BQ in treating acute gouty arthritis (AGA) and HUA.MATERIALS AND METHODSAnalyzing BQ's signaling pathways for gout treatment via network pharmacology. The HUA model was induced orally with adenine and potassium oxonate. The rat AGA model was established by MSU injection. In vitro, MH7A and RAW 246.7 cells were treated with LPS and MSU. Serum uric acid, creatinine, and urea nitrogen levels were evaluated. Kidney and ankle joint pathology was observed via HE staining. Inflammatory signaling pathway proteins, epithelial-mesenchymal transition (EMT) pathway proteins, and uric acid metabolism-related proteins were detected by Western blot.RESULTS1780 potential targets for gout treatment were identified, and 1039 target proteins corresponding to BQ's active ingredients were obtained. Pathway enrichment analysis revealed BQ improved gout mainly through inflammatory pathways. Experimental results showed BQ could reduce serum uric acid level and increase uric acid clearance rate by regulating the expression of adenosine deaminase (ADA), and organic anion transporter 1 (OAT1) and glucose transporter 9 (GLUT9) in HUA mice. BQ could improve renal function and injury by inhibiting the NLRP3 pathway in HUA mice' kidneys. Additionally, BQ could alleviate ankle joint swelling and synovial injury, inhibit the TLR4/NLRP3 pathway, and reduce levels of inflammatory factors including interleukin 6 (IL-6), interleukin 1β (IL-1β), and tumor necrosis factor-alpha (TNF-α) in AGA rats. The main component of BQ, brucine, could inhibit the activation of NLRP3/NF-κB pathway induced by MSU and reduce the expression level of inflammatory factors (IL-6, IL-1β, and TNF-α) in macrophages. Brucine could inhibit the activation of the EMT pathway and reduce the expression level of inflammatory factors (IL-6, TNF-α) in human fibroblast-like synoviocytes (MH7A cells) induced by MSU.CONCLUSIONSBQ effectively reduced serum uric acid levels, improved kidney and joint damage, and ameliorated the inflammatory response caused by MSU. Its main component, brucine, effectively improved the inflammatory response and reduced the invasive ability of synoviocytes induced by MSU.

01 Jan 2025·Journal of Pharmaceutical and Biomedical Analysis

A UPLC-MS/MS coupled with GC-MS method for quantification of twenty-one chemical ingredients from Suxiao Jiuxin pill in multiple tissue of rat and its application to tissue distribution study

Article

Author: Geng, Tong ; He, Jun ; Wang, Yuli ; Wei, Shujie ; Zhu, Yameng ; Zhou, Hong ; Zhou, Shuting ; Wang, Qilong ; Jiang, Yongping ; Liu, Yang ; Shang, Ye

Suxiao Jiuxin pill (SJP) was a commonly-used traditional Chinese medicine for treating cardiovascular diseases. It was composed of the rhizome of Ligusticum chuanxiong Hort. and Borneolum Syntheticum. The distribution of SJP in vivo was still ambiguous. A UPLC-MS/MS coupled with GC-MS method was developed to quantify twenty-one chemical ingredients in multiple tissues from rat after administration of SJP. Protein precipitation and liquid-liquid microextraction were both utilized in sample pretreatment. All analytes were detected under acceptable specificity, linearity (correlation coefficient > 0.992), sensitivity (LLOQ < 12.5 ng/mL), precision (RSD < 14.8 %), accuracy (RE < ±14.6 %), extraction recovery (between 52.8 % and 124.1 %), matrix effect (ranged from 60.5 % and 149.7 %) and stability (RE < ±16.0 %). The established method was successfully applied in the tissue distribution study of SJP in rats. As a result, the distribution characteristics of ten analytes were clearly elucidated, including borneol, isoborneol, ligustilide, senkyunolide A, ferulic acid, senkyunolide I, levistolide A, neocnidilide, senkyunolide H and angelicide. The information provided by this research was greatly meaningful for the active chemical ingredient exploration and clinical application of SJP.

News (Medical) associated with Tianjin University of Traditional Chinese Medicine

29 Oct 2024

·www.prnewswire.com

The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris

PAIRS, Oct. 28, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. Continue Reading (Group Photo at the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases) A key highlight of the WCCM was the Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases on October 26. Hosted by the Industry-Education Integration Promotion Committee of the World Federation of Chinese Medicine Societies (WFCMS) and organized by Jimon Group, the seminar highlighted the latest research achievements and clinical applications of Chinese medicine in cardiovascular diseases. The event aimed to explore the significant value of Chinese medicine in the prevention and treatment of cardiovascular and cerebrovascular diseases, promote in-depth integration of traditional Chinese and modern medicine, and enhance benefits for patients worldwide. Ramon Maria Calduch, Chairman of the Supervisory Board of the WFCMS; Zhang Boli, Vice President of the WFCMS, Senior Researcher at the Chinese Academy of Engineering, and a leading practitioner in Chinese medicine; and Niu Liwei, Vice President of the WFCMS Industry-Education Integration Promotion Committee and Chairman of Jimon Group were among the eminent attendees. Other celebrated participants included Liu Xiaohan, Secretary of the Hebei Pharmaceutical Industry Association, and Wang Yi, Secretary of the Party Committee of the Institute of Chinese Medicine at Tianjin University of Traditional Chinese Medicine. During the launch of the Chinese Medicine for Global Health Industry Expansion Plan, the Jimon Group Chairman, Mr. Niu, elaborated on the landmark initiative. He explained that Jimon Group intends to further the international expansion of Chinese medicine, and establish a Chinese Medicine Industry-Education Integration Expansion Center in Paris, with the goal of contributing its expertise and resources to the creation of a global health community. The WCCM also featured a signing ceremony to formalize collaborations between Jimon Group and several entities, including the WFCMS Industry-Education Integration Promotion Committee, the Association des Ingénieurs Chinois en France, the International Chinese Medicine and Healthcare General Association of the U.S.A., and Canada-based United Wings Enterprise Inc. Through these partnerships, Jimon Group seeks to expand its market reach while enhancing the adaptability and competitiveness of its products by utilizing local resources. The ultimate goal is to broaden the reach and improve the recognition and implementation of Chinese medicine in global health practices. During the roundtable dialogue session, leading practitioners and researchers engaged in a lively discussion on the progress and future of Chinese medicine in treating cardiovascular and cerebrovascular diseases. Eminent leaders in the field from Germany, Australia, and Canada exchanged ideas on the global expansion of Chinese medicine, focusing on its cultural inheritance, innovations, and international collaboration. Jimon Group's involvement in the WCCM not only showcased its robust capabilities and remarkable achievements in the realm of Chinese medicine, but also highlighted its role in advancing the practice on a global scale. Looking forward, the company remains committed to its mission of "Inheriting the culture of Chinese medicine and leading the future of health," with plans to increase its investment in scientific research. In doing so, Jimon Group aims to champion both the cultural heritage and the latest innovations in Chinese medicine, striving to substantially impact the global prevention and treatment of cardiovascular and cerebrovascular diseases. SOURCE Jimon Group WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

26 Jan 2024

·www.drugs.com

Acupuncture Tied to Improvements in Poststroke Motor Aphasia

FRIDAY, Jan. 26, 2024 -- Acupuncture may improve language function in patients with poststroke motor aphasia, according to a study published online Jan. 22 in JAMA Network Open . Boxuan Li, from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in China, and colleagues investigated the effects of acupuncture on language function, neurological function, and quality of life in patients with poststroke motor aphasia. The analysis included 252 adult patients with poststroke motor aphasia (Oct. 21, 2019, to Nov. 13, 2021) randomly assigned to six weeks of manual acupuncture or sham acupuncture. The researchers found that compared with sham treatment, the manual acupuncture group had significant increases in aphasia quotient (AQ) of the Western Aphasia Battery (difference, 7.99 points) and Chinese Functional Communication Profile (CFCP) scores (difference, 23.51 points) at week 6. These significant improvements persisted at six-month follow-up (AQ: difference, 10.34; CFCP: difference, 27.43). "The study results confirmed that poststroke motor aphasia was the dominant condition affected by the acupuncture treatment, indicating that acupuncture might serve as an adjunctive treatment for patients with poststroke motor aphasia," the authors write. "In addition, the clinical effects and safety results provide evidence for policymakers, clinicians, and patients regarding the management of poststroke aphasia with acupuncture." Abstract/Full Text Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions. Posted January 2024 More news resources FDA Medwatch Drug Alerts Daily MedNews News for Health Professionals New Drug Approvals New Drug Applications Drug Shortages Clinical Trial Results Generic Drug Approvals Subscribe to our newsletter Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Jul 2021

·www.globenewswire.com

Universe Pharmaceuticals INC Hosts Reception for Member of

Ji’an, Jiangxi, China, July 26, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced the Company hosted a reception on July 20, 2021 for Mr. Boli Zhang, a member of the Chinese Academy of Engineering, and a group of experts from Tianjin University of Traditional Chinese Medicine. Representatives from the local government also attended the reception, including Mr. Zhibin Liu, deputy mayor of Ji'an City, and Mr. Runjin Peng, head of Ji'an County. Mr. Boli Zhang and the experts visited the Company’s production facilities, and Mr. Gang Lai, Chairman and CEO of the Company, introduced the Company’s core product, Guben Yanling Pill during the reception. Mr. Boli Zhang and the experts thought highly of the Company's achievements in bringing health benefits to people and society. Mr. Boli Zhang stated, “Guben Yanling Pill is a product made from ginseng, ophiopogon japonicus and schisandra chinensis in Shengmaiyin, and other medicinal materials good for kidney function. Furthermore, it helps relieving fatigue, palpitation, low back pain and general weakness and soreness, and addresses the common symptoms experienced by middle-aged and elderly people. With the gradually increasing aging population and consumption upgrades, Guben Yanling Pill has huge market potential, especially in the Southeast Asian market.” Mr. Gang Lai, Chairman and CEO of Universe Pharmaceuticals INC, commented, “I would like to thank Mr. Boli Zhang and the experts from Tianjin University of Traditional Chinese Medicine for pointing out the direction for our technological innovation in the future. We expect to strengthen our research and development efforts, accelerate the construction of our research and development platform, explore technological cooperation with industry partners, and cooperate closely with Mr. Boli Zhang’s team so as to bring our technological innovation to a higher level.” About Universe Pharmaceuticals INC Universe Pharmaceuticals INC, headquartered in Ji’an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company’s products are sold in 30 provinces of China. For more information, visit the company’s website at . Forward-Looking Statements All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC. For more information, please contact: Ascent Investors Relations LLCTina XiaoPresidentPhone: 917-609-0333Email: tina.xiao@ascent-ir.com

100 Deals associated with Tianjin University of Traditional Chinese Medicine

100 Translational Medicine associated with Tianjin University of Traditional Chinese Medicine

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Jiashen Tablets	Chronic heart failure More	Phase 2
Danzhi Qing'e tablets	Menopausal symptoms More	Phase 2
Sanye Tablets	Diabetes Mellitus, Type 2 More	Phase 2
CN118236500 ( PD-1 )	Neoplasms More	Discovery
Ganqing Granules	Nonalcoholic Steatohepatitis More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis